Postthrombolytic Antiplatelet Use for Patients with Intercerebral Hemorrhage without Extensive Parenchymal Involvement Does Not Worsen Outcome

Background and Purpose  It is unclear whether postthrombolytic antiplatelet (AP) therapy after thrombolytic-related hemorrhage without extensive parenchymal involvement (THEPI) affects the clinical outcome. This study explored whether AP administration in patients with THEPI affects short- and long-term outcomes.

Methods  All of the data for this study were collected from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) registry. Patients with THEPI were assigned to either the AP (AP therapy should be commenced 24 h after intravenous thrombolysis) or AP-naive groups. THEPI was defined according to European-Australasian Acute Stroke Study II criteria. The 90-day functional outcome, 7-day National Institutes of Health Stroke Scale (NIHSS) score, and 7-day and 90-day mortalities were compared between the AP and AP-naive groups. Logistic regression analysis was used to evaluate the effects of AP therapy on the short- and long-term clinical outcomes.

Results  Of the 928 patients enrolled from those in the TIMS-China registry ($n=1,440$), 89 (9.6%) had nonsymptomatic intracerebral hemorrhage (ICH) within 24–36 h after thrombolysis; 33 (37%) of these patients were given AP therapy (AP group) and 56 (63%) were not (AP-naive group). No significant differences were found for the risk of 7-day aggravated ICH ($p=0.998$), 7-day NIHSS score ($p=0.5491$), 7-day mortality [odds ratio (OR)=$3.427$; 95% confidence interval (95% CI)=$0.344–34.160$; $p=0.294$], 90-day mortality (OR=$0.788$, 95% CI=$0.154–4.040$, $p=0.775$), or modified Rankin score 5 or 6 at 90-days (OR=$1.108$, 95% CI=$0.249–4.928$, $p=0.893$) between the AP and AP-naive groups after THEPI.

Conclusions  Early administration of postthrombolytic AP therapy after THEPI does not worsen either the short- or long-term outcome. AP therapy may be a reasonable treatment option for patients with THEPI to reduce the risk of ischemic stroke recurrence.

Key Words  ischemic stroke, thrombolytic-related hemorrhage, antiplatelet therapy, outcome.

INTRODUCTION

Intravenous thrombolysis with alteplase [a recombinant tissue plasminogen activator (rt-PA)] is the only approved treatment for acute ischemic stroke.1,2 However, the potential increased risk of postthrombolytic hemorrhagic transformation (HT), including thrombolytic-related hemorrhage without extensive parenchymal involvement (THEPI), limits its application.3-6 The early administration of AP therapy after THEPI is neither recommended nor discouraged by the guidelines. The guidelines of the American Heart Association/American Stroke Association suggest that HT within an ischemic stroke may have a different course and natural history from intracerebral hemorrhage (ICH).7 However, many cli-

©This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received  June 11, 2014
Revised  October 1, 2014
Accepted  October 1, 2014

Correspondence
Yongjun Wang, MD
Department of Neurology,
Beijing Tian Tan Hospital,
Capital Medical University,
No. 6 Tiantan Xili,
Dongcheng District,
Beijing 100050, China
Tel  +86-13911172565
Fax  +86-106-709-8350
E-mail  yongjunwang1962@gmail.com
nicians are still reluctant to continue AP therapy after THEPI. Several controversial findings regarding THEPI may influence the clinical outcome. The administration of AP therapy for THEPI remains a matter of debate. The findings of one retrospective study suggest that the early administration of antithrombotics is not associated with aggravation of HT and poor short-term outcome. However, in the current study HT was defined according to cranial magnetic resonance imaging (MRI) series, and thrombolysis was administered to some of the patients (46.7%). There have been few studies of the effects of early administration of AP therapy on the long-term outcome for patients with THEPI based on cranial computed tomography (CT).

The relationship between postthrombolytic AP therapy and clinical prognosis was assessed in patients with THEPI from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) registry. The hypothesis that early AP therapy worsens the outcome of postthrombolytic hemorrhage without extensive parenchymal involvement was tested.

METHODS

Subjects
The data for this study were collected from the TIMS-China registry, which is a national prospective stroke registry of thrombolytic therapy with intravenous rt-PA in patients with acute ischemic stroke in China. Nationwide, 67 centers participated in this stroke registry between May 2007 and April 2012. The demographics, clinical characteristics, cranial CT scans, medical therapies, and thrombolysis data were collected, and all of the patients were followed up for 3 months. All patients or their caregivers were interviewed at the clinic or by telephone. The physicians performed the data collection during the follow-up period. Eligible patients received thrombolysis within a 4.5-h poststroke time window. Patients with a National Institutes of Health Stroke Scale (NIHSS) score of ≥25 were excluded. Treatment information regarding the use of aspirin (ASA), clopidogrel (CLP), and other AP therapies commenced 24 h after thrombolysis was recorded in the TIMS-China case-report form. Patients with postthrombolytic nonsymptomatic ICH (non-sICH) were assigned to the AP group (AP therapy should have commenced within 24 h after intravenous thrombolysis) or the AP-naive group (AP therapy should not have commenced within 14 days after thrombolysis and hemorrhage disappeared on CT scan). Those on ASA only (21 cases), CLP only (10 cases), or dual AP therapy (2 cases) were not analyzed separately due to the smallness of the sample. The TIMS-China registry was approved by ethics committee of Beijing Tian Tan Hos-pital in 2006. The data from the TIMS-China registry was anonymized before access and analysis by all researchers, who were blind to the patient treatment assignment. All patients or his/her legal representatives provided written informed consent to participation before being entered in the registry.

Outcome analysis
Follow-up CT scans were collected at 24–36 h and 7 days. All follow-up CT scans demonstrating HT were rated according to European Cooperative Acute Stroke Study II (ECASS II) classification, as follows: HI1, small petechiae; HI2, confluent petechiae; PH1, hematoma in <30% of the infarcted area, with a mild space-occupying effect; and PH2, hematoma in >30% of the infarcted area, with a significant space-occupying effect. HT was also often divided into symptomatic ICH (sICH) and hemorrhage without extensive parenchymal involvement based on the deterioration in neurologic status. According to ECASS II criteria, sICH was defined as an increase in NIHSS score of ≥4 points from baseline for neurologic status in the first 24 h after thrombolysis and the presence of HT on the follow-up CT scan at 24–36 h. Patients with sICH were excluded from the present study. The remaining patients with thrombolysis-related HTs were labeled as having thrombolytic-related hemorrhage without extensive parenchymal involvement. Aggravation of HT was defined as either enlargement of the original HT or newly developed HT within the infarcted area. All scans were interpreted independently by two experienced neuroradiologists who were blinded to the clinical data. In cases of discrepancy between the two raters, the scans were reviewed simultaneously by a central radiological adjudication committee. The primary outcome measures included functional outcome at 90 days [functional independence was defined as a modified Rankin Scale (mRS) score of 0–6], NIHSS score at 7 days, and mortality at 7 and 90 days.

Statistical analysis
Data are presented as mean±SD values, or as frequencies for categorical variables. Pearson's chi-square (χ²) test was used for comparisons of categorical variables. Continuous variables were analyzed using the t-test or Mann-Whitney U test. Percentage proportions of outcome events were calculated by dividing the number of events by the total number of patients. A separate multivariable logistic regression was performed for each outcome variable. Odds ratios with 95% confidence intervals were calculated using the AP-naive group after thrombolytic-related hemorrhage without extensive parenchymal involvement as the reference group. The threshold for statistical significance was set at p<0.05. All statistical analyses were performed using SAS software.
RESULTS

Of the 1,440 patients enrolled on the TIMS-China registry at 67 centers across China, the data of 928 patients were included in the data analysis; of these, 89 patients had THEPI within 24–36 h. It has been reported that 9.6% of thrombolysis patients in China transform to asymptomatic hemorrhage. In the present study, 33 of the 89 THEPI patients (37%) who were administered AP therapy 24–36 h, and the remaining 56 without AP therapy (63%) transformed to asymptomatic hemorrhage (Fig. 1). The baseline characteristics of the patients with asymptomatic HT postthrombolytic therapy with or without AP drugs are given in Table 1. The findings demonstrate that more male asymptomatic patients with HT were administered postthrombolytic AP agents than their female counterparts. There were 38, 30, 15, and 6 patients who transformed to the H12, H11, PH1, and PH2 subtypes of asymptomatic hemorrhage, respectively, after thrombolytic therapy, of which 13, 15, 3, and 2 with the H11 received AP drugs. The bleeding ratio of patients with asymptomatic HT after thrombolysis in the AP group was 9.09% ($n=3$), while that of patients in the AP-naïve group was 7.14% ($n=4$). Furthermore, two of the AP-naïve patients with the PH2 subtype suffered hematoma expansion, while only one of the AP-group patients with the PH2 subtype suffered hematoma enlargement (Figs. 2 and 3). Follow-up after 7 days revealed NIHSS scores of 9.19±7.86 and 10.45±8.49 in the AP and AP-naïve groups.

Table 1. Baseline characteristics of THEPI patients with (AP group) and without (AP-naïve group) AP therapy

|                          | AP group ($n=33$) | AP-naïve group ($n=56$) | $p$   |
|--------------------------|-------------------|-------------------------|-------|
| Gender (male)            | 10 (30.30)        | 30 (53.57)              | 0.033 |
| Age (years)              | 65.12±9.82        | 66.70±9.72              | 0.427 |
| History of hypertension  | 17 (51.52)        | 32 (57.14)              | 0.606 |
| History of diabetes      | 3 (9.09)          | 9 (16.07)               | 0.542 |
| History of atrial fibrillation | 11 (33.33)      | 20 (35.71)              | 0.812 |
| History of smoking       | 12 (36.36)        | 13 (23.21)              | 0.182 |
| Postthrombolytic AP use  | 5 (15.15)         | 7 (12.50)               | 0.974 |
| Time rt-PA administered after symptom onset (hours) | 3.06±0.81 | 2.72±0.68 | 0.451 |
| Serum glucose (mmol/L)   | 6.84±1.21         | 7.34±2.85               | 0.590 |
| Systolic blood pressure (mm Hg) | 140.06±24.11 | 151.95±22.04 | 0.126 |
| Dystolic blood pressure (mm Hg) | 81.00±12.42 | 87.54±13.80 | 0.204 |
| History of hyperlipidemia| 2 (6.06)          | 2 (3.57)                | 0.986 |
| TOAST stroke type        |                   |                         |       |
| Atherothrombotic          | 22 (66.67)        | 28 (50.00)              | 0.303 |
| Cardioembolic             | 9 (27.27)         | 22 (39.29)              |       |
| Other/unknown             | 2 (6.06)          | 6 (10.71)               |       |
| Dose of rt-PA (mg/kg)     | 0.85±0.08         | 0.87±0.12               | 0.265 |
| NIHSS score before thrombolysis | 14.42±5.86   | 16.23±6.98              | 0.220 |
| History of mRS            | 3 (3.37)          | 33 (4.06)               | 0.637 |
| History of TIA            | 0 (0.00)          | 3 (5.36)                | 0.456 |
| History of stroke         | 4 (12.12)         | 11 (19.64)              | 0.360 |
| Occlusion of total ICA    | 5 (16.67)         | 3 (6.12)                | 0.261 |
| Occlusion of proximal MCA | 5 (16.67)         | 3 (6.12)                | 0.261 |

The data are mean±SD or n (% values).

AP: antiplatelet, ICA: internal carotid artery, MCA: middle cerebral artery, rt-PA: recombinant tissue plasminogen activator, THEPI: thrombolytic-related hemorrhage without extensive parenchymal involvement, TIA: transient ischemic attack, TOAST: Trial of Org 10172 in Acute Stroke Treatment.
respectively (p = 0.549).

Analysis of the data without adjustment for covariates revealed that administration of postthrombolytic AP therapy improved the clinical outcomes at 90 days of follow-up (i.e., 90-day mortality, mRS score 0–2, and mRS score 5 or 6) in patients with THEPI. After adjustment for age, sex, baseline NIHSS score, and dose of rt-PA using a logistic regression model, the use of postthrombolytic AP therapy still exhibited a favorable trend, although not a statistically significant one (Table 2), and there was no increase in mortality or in the mRS score 5 or 6 ratio. Subgroup analysis of THEPI revealed that postthrombolytic AP therapy did not adversely affect the clinical outcomes of patients with the H11, H12, or PH1 subtypes (Table 3).

**DISCUSSION**

While the use of AP therapy after THEPI has not been recommended in any studies, the present study showed that postthrombolytic AP therapy in such patients did not worsen the short- or long-term prognosis, and that the early use of AP therapy after THEPI might thus be relatively safe for patients enrolled in the TIMS-China registry. In addition, although aggravation of HT was observed more frequently in patients with PH2 than in those with the other subtypes, the administration of AP therapy after THEPI was not associated with neurological deterioration. Therefore, the results of the present study suggest that the use of AP therapy after THEPI—especially the H11, H12, and PH1 subgroups—might be reasonable for the prevention of subsequent ischemic stroke.

**THEPI in China**

The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study found remarkably low rates of nonsymptomatic HT (4.5%), as did a large observational study of intravenous thrombolysis, the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST; 9.6%). In TIMS-China, this figure was 9.5%. However, there were higher rates of asymptomatic hemorrhage (39.6%) in ECASS II. Earlier initiation of thrombolysis may be the reason for the lower asymptomatic hemorrhage rates in NINDS, SITS-MOST, and TIMS-China compared to ECASS II. Direct comparison of the non-sICH rates among the different studies may also be hampered by variability in definitions and differences in the timing of imaging.

**Table 2. Functional outcomes for THEPI with and without postthrombolysis AP therapy**

| Outcome                      | Postthrombolytic AP therapy | Unadjusted OR (95% CI) | p   | Adjusted OR (95% CI) | p   |
|------------------------------|-----------------------------|------------------------|-----|----------------------|-----|
| Mortality at 7-day follow-up | Yes (n=33; 37%)             | 1.185 (0.049–1.696)    | 0.113 | 3.427 (0.344–34.160) | 0.294 |
|                             | No (n=56; 63%)              |                        |     |                      |     |
| Mortality at 90-day follow-up| Yes (n=33; 37%)             | 0.690 (0.086–0.818)    | 0.036 | 0.788 (0.154–4.040)  | 0.775 |
|                             | No (n=56; 63%)              |                        |     |                      |     |
| mRS score 0-1 at 90-day follow-up| Yes (n=33; 37%)           | 1.191 (1.089–3.409)    | 0.055 | 1.461 (0.532–4.011)  | 0.462 |
|                             | No (n=56; 63%)              |                        |     |                      |     |
| mRS score 0-2 at 90-day follow-up| Yes (n=33; 37%)           | 1.253 (10.153–4.416)   | 0.021 | 1.568 (0.609–4.039)  | 0.351 |
|                             | No (n=56; 63%)              |                        |     |                      |     |
| mRS score 5 or 6 at 90-day follow-up| Yes (n=33; 37%)         | 0.720 (0.547–0.929)    | 0.014 | 1.108 (0.249–4.928)  | 0.893 |

Adjusted covariates (logistic regression model): age, sex, baseline NIHSS score, and dose of rt-PA. AP: antiplatelet, CI: confidence interval, NIHSS: National Institutes of Health Stroke Scale, OR: odds ratio, rt-PA: recombinant tissue plasminogen activator, THEPI: thrombolytic-related hemorrhage without extensive parenchymal involvement.  

TOTAL: 308 J Clin Neurol 2015;11(4):305-310
Kim et al.\textsuperscript{11} found that the use of AP therapy was reduced to after THEPI. Functional outcomes for THEPI subgroups (HT1+HT2+PH1) with and without AP therapy after thrombolysis

Table 3. Functional outcomes for THEPI subgroups (HT1+HT2+PH1) with and without AP therapy after thrombolysis

| Outcome | Postthrombolysis AP therapy | Unadjusted OR | Adjusted OR |
|---------|-----------------------------|---------------|-------------|
|         | Yes (n=31; 37%) | No (n=52; 63%) | OR (95% CI) | p | OR (95% CI) | p |
| Mortality at 7-day follow-up | 1 (3.33) | 2 (3.85) | 0.690 (0.060–7.973) | 0.766 | 1.251 (0.0860–18.297) | 0.870 |
| Mortality at 90-day follow-up | 2 (6.67) | 4 (7.69) | 0.679 (0.116–3.969) | 0.667 | 0.429 (0.0686–2.717) | 0.370 |
| mRS score at 90-day follow-up | | | | | |
| 0 or 1 | 11 (35.48) | 13 (25.00) | 1.291 (0.480–3.474) | 0.612 | 1.597 (0.563–4.528) | 0.379 |
| 0–2 | 14 (45.16) | 17 (32.69) | 1.287 (0.500–3.313) | 0.601 | 1.724 (0.236–3.706) | 0.275 |
| 5 or 6 | 3 (9.68) | 4 (7.69) | 1.056 (0.218–5.105) | 0.946 | 0.693 (0.139–3.453) | 0.654 |

Except where stated otherwise, data are n (%) values. Adjusted covariates (logistic regression model): age, sex, baseline NIHSS score, and dose of rt-PA.

AP: antiplatelet, CI: confidence interval, NIHSS: National Institutes of Health Stroke Scale, OR: odds ratio, rt-PA: recombinant tissue plasminogen activator, THEPI: thrombolytic-related hemorrhage without extensive parenchymal involvement.

AP therapy after THEPI

Kim et al.\textsuperscript{11} found that the use of AP therapy was reduced to about 73% in patients who had hemorrhagic infarction and noncardioembolic stroke. In the present study, only about 37% of Chinese patients were administered AP therapy after THEPI, suggesting that physicians in China were cautious about using AP therapy in such patients. The probable explanation for this reluctance was that the physicians worried that HT would aggravate the clinical outcome. The increase, however, may also be attributable to the increase in the number of medical disputes in China.\textsuperscript{20} The retrospective study of Kim et al.\textsuperscript{11} suggested that the early administration of antithrombotics was not related to the aggravation of HT and poor short-term outcome. However, in that study HT was defined according to cranial MRI series, and the long-term clinical outcome was not assessed. In the present study, HT, defined as cranial CT and THEPI, was defined clinically (worsening of the NIHSS score by <4 points from the baseline NIHSS score). We attempted to ascertain whether postthrombolytic AP therapy in patients with THEPI was associated with a worse outcome. However, the present findings are in agreement with that of Kim et al.\textsuperscript{11–12} AP therapy after THEPI does not lead to a worse clinical outcome.

The assumption was made at the start of this study that the risks of early administration of AP therapy after THEPI would outweigh the benefits. However, the study showed that postthrombolytic AP therapy for patients with THEPI does not worsen either the short- or long-term clinical outcome. Given the differences in proportions of patients taking AP therapy between the subtypes of THEPI, and the tendency toward a reduction in AP therapy among those with the PH2 subtype, the data were reanalyzed with only data from the H11, H12, and PH1 subgroups, with similar findings. The increased risk of aggravated HT at 7 days found for those with the PH2 type of THEPI who were treated with early AP therapy must be interpreted with caution, since the effect was measured in a relatively small number of patients. However, this finding perhaps indicates that physicians should be more circumspect when considering postthrombolytic APs therapy in PH2-type patients.

Study limitations

This study was subject to some limitations. The sample was relatively small, which may have had a subtle effect (either positive or negative) on the outcome of THEPI. It should be noted that the application of AP therapy did not follow the randomized, double-blind principles of clinical study, which may have resulted in different proportions of patients being given AP therapy between the various subtypes, possibly affecting the observed tendency to decline AP therapy in the PH2 subtype. This might explain the favorable trend of an mRS score 0 or 1 or an mRS score 0–2 outcome in the AP group. However, in the subgroup (H11+H12+PH1) analysis, the early use of AP therapy for THEPI still does not still worsen either the short- or long-term clinical outcome. A double-blinded, placebo-controlled design would have prevented this bias.

In summary, notwithstanding the aforementioned study limitations, the present results suggest that AP therapy in patients with THEPI in China does have a negative effect on the clinical prognosis. Evidence was found that early administration of postthrombolytic AP therapy after THEPI does not worsen either the short- or long-term clinical outcome. AP therapy in patients with THEPI, and especially the H11, H12, and PH1 subgroups, may be a safe intervention for stroke recurrence.

Conflicts of Interest

The authors have no financial conflicts of interest.

REFERENCES

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
2. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Inves-
tigators. Lancet 1998;352:1245-1251.
3. Sussman ES, Connolly ES Jr. Hemorrhagic transformation: a review of the rate of hemorrhage in the major clinical trials of acute ischemic stroke. Front Neurol 2013;4:69.
4. Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006;37:556-561.
5. Molina CA, Alvarez-Sabin J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002;33:1551-1556.
6. Kerenyi L, Kardos L, Szász J, Szatmári S, Bereczki D, Hegedüs K, et al. Factors influencing hemorrhagic transformation in ischemic stroke: a clinicopathological comparison. Eur J Neurol 2006;13:1251-1255.
7. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-2236.
8. Park JH, Ko Y, Kim WJ, Jang MS, Yang MH, Han MK, et al. Asymptomatic hemorrhagic transformation really innocuous? Neurology 2012;78:421-426.
9. Kent DM, Hinchen J, Price LL, Levine SR, Selker HP. In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous? Stroke 2004;35:1141-1146.
10. Libman R, Kwiakowski T, Lyden P, Grotta JC, Tilley BC, Fagen SC, et al. Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome. J Stroke Cerebrovasc Dis 2005;14:50-54.
11. Kim JT, Heo SH, Park MS, Chang J, Choi KH, Cho KH. Use of anti-thrombotics after hemorrhagic transformation in acute ischemic stroke. PLoS One 2014;9:e89798.
12. Liao XL, Wang CX, Wang YL, Wang CJ, Zhao XQ, Zhang LQ, et al. Implementation and outcome of thrombolysis with alteplase 3 to 4.5 h after acute stroke in Chinese patients. CNS Neurosci Ther 2013;19:43-47.
13. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-282.
14. Kimura K, Iguchi Y, Shibazaki K, Aoki J, Terasawa Y. Hemorrhagic transformation of ischemic brain tissue after t-PA thrombolysis as detected by MRI may be asymptomatic, but impair neurological recovery. J Neurol Sci 2008;272:136-142.
15. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry 2008;79:1093-1099.
16. Jickling GC, Liu D, Stamova B, Ander BP, Zhan X, Lu A, et al. Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab 2014;34:185-199.
17. Jia W, Zhou L. Use of antiplatelets. A survey of secondary prevention of ischemic stroke with intracranial hemorrhage history in Chinese patients. Neurosciences (Riyadh) 2011;16:335-339.
18. Kablau M, Kreisel SH, Sauer T, Binder J, Szabo K, Hennerici MG, et al. Predictors and early outcome of hemorrhagic transformation after acute ischemic stroke. Cerebrovasc Dis 2011;32:334-341.
19. Dzialowski I, Pexman JH, Barber PA, Demchuk AM, Buchan AM, Hill MD, et al. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry. Stroke 2007;38:75-79.
20. Wang Y, Liao X, Zhao X, Wang DZ, Wang C, Nguyen-Huy Nh MN, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke 2011;42:1658-1664.